This included, for example, known tumor suppressor genes (e.g., DACH1, MGAT2, SENP6, SMAD4) that were jointly underexpressed or known cancer census genes (e.g., BCL11B, CD74, GATA3, MAFB, PDGFB) that were jointly overexpressed in all three comparisons of imatinib-resistant patients to the individual CML phases. The gene discussed is SMAD4; the disease is cancer.